Pexerelgon clinical trials
Also written AZD5462.
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2021
How each study uses Pexerelgon is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- AZD5462
- 7
Studies by the year they started
7 studies that test it; most in 2024 (3)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 2 |
| 2024 | 3 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Studies
Open first, then newest update. How each study uses Pexerelgon is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- A Phase IIb Study of AZD5462 in Patients With Chronic Heart FailureCompletedPhase 2AstraZenecaNCT06299826Written as AZD5462
- A Study to Investigate the Pharmacokinetics, Safety and Tolerability of AZD5462 in Participants With Renal ImpairmentCompletedPhase 1AstraZenecaNCT06661733Written as AZD5462
- A Phase Ib Study of AZD5462 on Top of Dapagliflozin in Participants With Heart Failure and Moderate Renal ImpairmentTerminatedPhase 1AstraZenecaNCT06639087Written as AZD5462
- A Study Designed to Assess the Mass Balance Recovery, Absorption, Metabolism, Excretion of [14C]AZD5462 and the Absolute Bioavailability of AZD5462CompletedPhase 1AstraZenecaNCT06989983Written as AZD5462 film-coated tablet
- A Study to Assess the Effect of AZD5462 on the Pharmacokinetics of Midazolam, Rosuvastatin and DigoxinCompletedPhase 1AstraZenecaNCT05395117Written as AZD5462
- A Bioavailability and Food Effect Study of AZD5462 in Healthy VolunteersCompletedPhase 1AstraZenecaNCT05512806Written as AZD5462
- A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD5462 Following Single and Multiple Ascending Dose Administration to Healthy VolunteersCompletedPhase 1AstraZenecaNCT04994106Written as AZD5462